European Myocardial Infarction Market to Reach $3.8 Billion by 2035

European myocardial infarction market was valued at $2.4 billion in 2025 and is projected to reach $3.8 billion by 2035, growing at a CAGR of 4.70% during the forecast period (2026–2035). Market growth is primarily driven by the rising burden of cardiovascular diseases across Europe. According to the World Health Organization, cardiovascular diseases account for nearly 32% of total global deaths, with a significant share reported across European countries due to aging populations and lifestyle-related risk factors. This increasing disease prevalence is boosting demand for advanced medical devices such as pacemakers, catheters, and implantable cardioverter defibrillators, particularly in hospitals and specialty cardiac centers.

Browse the full report description of “European Myocardial Infarction Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Interventional Procedures, Adjunct & Supportive Care), by Medical Device Type (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, Others), by End-User (Hospitals, Specialty Centres, ASCs), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/european-myocardial-infarction-market

Innovation Leaders Transforming the European Myocardial Infarction Market

The key players in the European myocardial infarction market include top companies such as Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, and GE HealthCare, among others. The market is witnessing steady growth due to the increasing adoption of minimally invasive interventional procedures and technologically advanced cardiac devices. Hospitals remain the primary end-users due to their advanced infrastructure, availability of skilled cardiologists, and growing patient inflow for acute cardiac care.

• In February 2026, Siemens Healthineers and Mayo Clinic expanded their strategic collaboration to enhance patient care through advanced imaging, AI, and minimally invasive interventional technologies. The partnership focuses on improving diagnostic accuracy and expanding access to innovative imaging solutions across multiple disease areas. Such advancements in imaging and interventional capabilities can indirectly support early detection and treatment planning for cardiovascular conditions, including myocardial infarction.

• In August 2025, Abbott received CE Mark approval in Europe for the expanded indication of its Navitor TAVI system to treat patients with severe aortic stenosis across all surgical risk categories. The minimally invasive valve replacement technology significantly broadens treatment access and supports advanced interventional cardiology adoption. This development strengthens the European cardiac device landscape, indirectly contributing to improved management of cardiovascular conditions including myocardial infarction.

• In October 2024, Medtronic received FDA approval for its Affera Mapping and Ablation System with Sphere-9 catheter, designed for advanced electrophysiology procedures in treating cardiac arrhythmias. The system integrates high-density mapping with dual-energy ablation to improve procedural efficiency and clinical outcomes. This innovation supports advancements in cardiac intervention technologies, indirectly strengthening treatment capabilities relevant to myocardial infarction management.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-

• By Treatment Type
• By Medical Device Type
• By End-User

• Competitive Landscape: Johnson & Johnson, Abbott, Medtronic, Siemens Healthineers, and GE HealthCare, among others.

Key questions addressed by the repor

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Myocardial Infarction Market Report Segment

By Treatment Type

• Pharmacological Treatment
• Interventional Procedures
• Adjunct & Supportive Care

By Device Type

• Left Ventricular Assist Device
• Pacemaker
• Catheters
• Implantable Cardioverter Defibrillator
• Others

By End-User

• Hospitals
• Specialty Centres
• ASCs

European Myocardial Infarction Market Report Segment by Country

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-myocardial-infarction-market